Compare Amgen, Inc. (AMGN) vs Moody's Corporation (MCO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Moody's Corporation — how do they compare? Amgen, Inc. trades at $363.66 (market cap $196.12B), while Moody's Corporation trades at $480.01 (market cap $85.12B). The key difference: Amgen, Inc. is far larger — about 2.3× Moody's Corporation's market cap, and Amgen, Inc. pays the higher dividend (2.77%). Which is the better fit depends on your goals.
| AMGN | MCO | |
|---|---|---|
Market Cap | $196.12B | $85.12B |
Sector | Health | Financials |
52-Week High | $388.16 | $539.61 |
52-Week Low | $271.18 | $412.23 |
Enterprise Value | $241.41B | $90.92B |
Dividend Yield | 2.77% | 0.85% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
MCO trades at $487.28, up 0.05% on the day, with a bullish technical signal supported by moving averages and strong fundamentals. The company reported Q1 2026 EPS of $4.33, beating estimates, and maintains robust profitability with a 31.69% net income margin. Recent news highlights Moody's AI initiatives, including new AI skills and integrations, positioning for growth in credit analytics. The stock is near its 52-week high, with support at $481 and resistance at $490.
Outlook remains positive with a consensus price target of $539.40, implying 11% upside, driven by earnings momentum and AI adoption. Risks include high valuation multiples (P/E 34.96) and dependence on debt issuance cycles. Institutional sentiment is bullish with 56% buy ratings, but overbought RSI levels suggest near-term consolidation potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Moody's Corporation
Moody's, along with S&P Ratings, is a leading provider of credit ratings on fixed income securities. Moody's ratings segment, known as Moody's Investors Service or MIS, includes corporates, structured finance, financial institutions, and public finance ratings. MIS represents a majority of the firm's revenue and profits. Moody's other segment is Moody's Analytics and consists of Research, Data, and Analytics or RD&A and Enterprise Risk Solutions or ERS. RD&A's products include credit research, quantitative credit scores, economic research, business intelligence, know your customer (KYC) tools, commercial real estate data and analytical tools, and training services. ERS includes risk management software solutions to financial institutions.
Read more on MCO →
